François Philippon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
François Philippon has a total of 418 co-authors. Here are the top co-authors by number of shared publications:
- Josep Rodés-Cabau
Laval University
14 shared publications - Jean Champagne
Quebec Heart and Lung Institute, Laval University, Quebec City, QC, Canada (J.R.-C., J.-M.P., J.C., P.V.-C., M.C., G.O., E.S.).
6 shared publications - Quentin Fischer
Quebec Heart and Lung Institute, Laval University, Québec City, QC, Canada
6 shared publications - Andrew D. Krahn
Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
5 shared publications - Jean-François Sarrazin
Department of Cardiology, Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Québec City, Québec, Canada
5 shared publications - Luis Nombela-Franco
Cardiovascular Institute, Hospital Clínico San Carlos, IdISSC, Madrid, Spain
5 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by Elsevier in Structural Heart
- Vol. 10 (11)
Conduction Disturbances Following EVOQUE Implantation: How to Anticipate Pacemaker Needs
- 5 June 2026
- Published by Elsevier in Structural Heart
- Vol. 10 (11)
Open AccessConduction Disturbances Following EVOQUE Implantation: How to Anticipate Pacemaker Needs
- 3 June 2026
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (9) , 1933-1935
Left Bundle Branch Area Pacing Based Solely on Electrocardiographic Criteria: There’s More to the Story
- 3 June 2026
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (9) , 1933-1935
Left Bundle Branch Area Pacing Based Solely on Electrocardiographic Criteria: There’s More to the Story
- 11 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (9) , 1124-1134
Long-Term Outcomes in Patients With New-Onset Left Bundle Branch Block Following TAVR
- 11 May 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (9) , 1124-1134
Long-Term Outcomes in Patients With New-Onset Left Bundle Branch Block Following TAVR
- 30 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (8) , e016288
Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR
BACKGROUND: Although ambulatory ECG (AECG) monitoring has been assessed after transcatheter aortic valve replacement (TAVR), its impact on life-threatening cardiovascular events remains unclear. This study aimed to evaluate whether systematic AECG monitoring after TAVR reduces life-threatening cardiovascular events during the first year of follow-up. METHODS: The study included 1217 consecutive patients who underwent TAVR and were discharged without a permanent pacemaker. Of these, 211 consecutive patients received systematic 14-day AECG monitoring at discharge as part of the RECORD registry. The remaining 1006 patients who underwent TAVR within the 3 years before and after the registry period without systematic AECG monitoring constituted the control group. The primary end point was a composite of sudden cardiac death, syncope/presyncope due to symptomatic arrhythmias, or stroke at 1-year. RESULTS: Baseline and procedural characteristics were similar between groups, except for a higher use of self-expandable valves in the control group ( P =0.005). Systematic AECG monitoring was associated with a lower incidence of the primary end point (1.9% versus 6.6%; adjusted hazard ratio, 0.27 [0.10–0.74]; P =0.011), mainly driven by a lower rate of sudden death or arrhythmic syncope/presyncope (0.9% versus 4.0%; adjusted hazard ratio, 0.22 [0.05–0.89]; P =0.034). All sudden death cases occurred in the control group, at a median of 96 (33–235) days after TAVR. New-onset atrial fibrillation was diagnosed in 8.9% of the systematic AECG patients (versus 1.8% in the control group; adjusted hazard ratio, 5.31 [2.47–11.38]; P P <0.001). CONCLUSIONS: Systematic AECG monitoring after TAVR enables earlier detection of severe arrhythmias and is associated with fewer life-threatening cardiovascular events within 1 year. These findings support the need for a randomized trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04298593.
- 30 April 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (8) , e016288
Systematic Ambulatory ECG Monitoring for Preventing Life-Threatening Cardiovascular Events Following TAVR
BACKGROUND: Although ambulatory ECG (AECG) monitoring has been assessed after transcatheter aortic valve replacement (TAVR), its impact on life-threatening cardiovascular events remains unclear. This study aimed to evaluate whether systematic AECG monitoring after TAVR reduces life-threatening cardiovascular events during the first year of follow-up. METHODS: The study included 1217 consecutive patients who underwent TAVR and were discharged without a permanent pacemaker. Of these, 211 consecutive patients received systematic 14-day AECG monitoring at discharge as part of the RECORD registry. The remaining 1006 patients who underwent TAVR within the 3 years before and after the registry period without systematic AECG monitoring constituted the control group. The primary end point was a composite of sudden cardiac death, syncope/presyncope due to symptomatic arrhythmias, or stroke at 1-year. RESULTS: Baseline and procedural characteristics were similar between groups, except for a higher use of self-expandable valves in the control group ( P =0.005). Systematic AECG monitoring was associated with a lower incidence of the primary end point (1.9% versus 6.6%; adjusted hazard ratio, 0.27 [0.10–0.74]; P =0.011), mainly driven by a lower rate of sudden death or arrhythmic syncope/presyncope (0.9% versus 4.0%; adjusted hazard ratio, 0.22 [0.05–0.89]; P =0.034). All sudden death cases occurred in the control group, at a median of 96 (33–235) days after TAVR. New-onset atrial fibrillation was diagnosed in 8.9% of the systematic AECG patients (versus 1.8% in the control group; adjusted hazard ratio, 5.31 [2.47–11.38]; P P <0.001). CONCLUSIONS: Systematic AECG monitoring after TAVR enables earlier detection of severe arrhythmias and is associated with fewer life-threatening cardiovascular events within 1 year. These findings support the need for a randomized trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04298593.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (2) , e015579
Risk of Delayed Atrioventricular Block in TAVR Recipients With Preexisting Right Bundle Branch Block
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 19 (2) , e015579
Risk of Delayed Atrioventricular Block in TAVR Recipients With Preexisting Right Bundle Branch Block
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014132
4D Digital Heart Model–Guided Left and Right Ventricular Lead Placement for Cardiac Resynchronization Therapy: Results of MAPIT-CRT Trial
BACKGROUND: Suboptimal left ventricular (LV) and right ventricular lead positioning has been associated with a lesser response to cardiac resynchronization therapy. The MAPIT-CRT (MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy) randomized controlled trial evaluated a novel, cardiac magnetic resonance–generated 4-dimensional phenomics cardiac magnetic resonance imaging (4DPcmr) lead placement strategy. METHODS: A total of 202 participants with New York Heart Association class II to IV heart failure on optimal medical therapy, LV ejection fraction ≤35%, and QRS duration ≥120 ms were analyzed from 7 Canadian sites. Participants were randomized to 4DPcmr-guided lead placement using a web-based application or standard lead placement. 4DPcmr-recommended LV and right ventricular (RV) lead locations were generated using the combined consideration of (1) regional scar distribution and burden, (2) maximal regional delay in LV peak systolic strain, and (3) maximal interlead distance. RESULTS: The primary end point, an increase in LV ejection fraction ≥5% at 6 months, was reached in 69 of 105 4DPcmr-guided participants (65.7%) versus 50 of 96 control participants (52.1%; risk ratio, 1.80 [95% CI, 1.02–3.17]; P =0.04). The absolute increases in LV ejection fraction observed for the respective study arms were 10.8% versus 5.8% ( P =0.01). No differences were identified in the secondary end points of all-cause mortality or heart failure hospitalization at 12 months, rate of adverse outcomes, or procedural times between the 2 study arms. CONCLUSIONS: 4DPcmr-guided LV/RV cardiac resynchronization therapy lead implantation using a practical web application was clinically feasible, safe, and was associated with greater LV ejection fraction improvement at 6 months versus standard of care with no increase in procedural times or complications. REGISTRATION: URL: https://clinicaltrials.gov/study/NCT01640769 ; Unique identifier: NCT01640769.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014132
4D Digital Heart Model–Guided Left and Right Ventricular Lead Placement for Cardiac Resynchronization Therapy: Results of MAPIT-CRT Trial
BACKGROUND: Suboptimal left ventricular (LV) and right ventricular lead positioning has been associated with a lesser response to cardiac resynchronization therapy. The MAPIT-CRT (MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy) randomized controlled trial evaluated a novel, cardiac magnetic resonance–generated 4-dimensional phenomics cardiac magnetic resonance imaging (4DPcmr) lead placement strategy. METHODS: A total of 202 participants with New York Heart Association class II to IV heart failure on optimal medical therapy, LV ejection fraction ≤35%, and QRS duration ≥120 ms were analyzed from 7 Canadian sites. Participants were randomized to 4DPcmr-guided lead placement using a web-based application or standard lead placement. 4DPcmr-recommended LV and right ventricular (RV) lead locations were generated using the combined consideration of (1) regional scar distribution and burden, (2) maximal regional delay in LV peak systolic strain, and (3) maximal interlead distance. RESULTS: The primary end point, an increase in LV ejection fraction ≥5% at 6 months, was reached in 69 of 105 4DPcmr-guided participants (65.7%) versus 50 of 96 control participants (52.1%; risk ratio, 1.80 [95% CI, 1.02–3.17]; P =0.04). The absolute increases in LV ejection fraction observed for the respective study arms were 10.8% versus 5.8% ( P =0.01). No differences were identified in the secondary end points of all-cause mortality or heart failure hospitalization at 12 months, rate of adverse outcomes, or procedural times between the 2 study arms. CONCLUSIONS: 4DPcmr-guided LV/RV cardiac resynchronization therapy lead implantation using a practical web application was clinically feasible, safe, and was associated with greater LV ejection fraction improvement at 6 months versus standard of care with no increase in procedural times or complications. REGISTRATION: URL: https://clinicaltrials.gov/study/NCT01640769 ; Unique identifier: NCT01640769.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014424
Safety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial
BACKGROUND: The LEADR (Lead Evaluation for Defibrillation and Reliability) trial evaluated the small-diameter (4.7F), lumenless, integrated bipolar OmniaSecure defibrillation lead. The trial exceeded primary safety and efficacy objective thresholds, demonstrating favorable efficacy at implant and a low rate of complications. Three-year term outcomes of the LEADR trial assessing the OmniaSecure lead are reported here. METHODS: The LEADR trial is a prospective, multicenter, single-arm clinical trial. Patients with an indication for de novo implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator were implanted with the OmniaSecure lead in standard right ventricle locations and followed at prespecified intervals. The lead was evaluated for safety, efficacy, and reliability through final follow-up. RESULTS: There were 643/657 patients (97.9%) successfully implanted with the OmniaSecure lead with a mean follow-up of 32.4±9.1 months (26% female, 61.9±12.9 years). Pacing capture threshold, pacing impedance, and R-wave amplitudes remained stable throughout. There was a 96.5% freedom from major study lead-related complications at 3 years. At 3 years, 22.3% of patients received appropriate therapies, that is, shock and antitachycardia pacing, with a 75.4% antitachycardia pacing efficacy. Inappropriate shock rate was 2.7% and 5.9% at 1 and 3 years, respectively. CONCLUSIONS: The final results of the LEADR trial demonstrated 3-year term safety, efficacy, and reliability of the OmniaSecure lead, emphasizing the potential utility of this lead in a wide variety of patients.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014424
Open AccessSafety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial
BACKGROUND: The LEADR (Lead Evaluation for Defibrillation and Reliability) trial evaluated the small-diameter (4.7F), lumenless, integrated bipolar OmniaSecure defibrillation lead. The trial exceeded primary safety and efficacy objective thresholds, demonstrating favorable efficacy at implant and a low rate of complications. Three-year term outcomes of the LEADR trial assessing the OmniaSecure lead are reported here. METHODS: The LEADR trial is a prospective, multicenter, single-arm clinical trial. Patients with an indication for de novo implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator were implanted with the OmniaSecure lead in standard right ventricle locations and followed at prespecified intervals. The lead was evaluated for safety, efficacy, and reliability through final follow-up. RESULTS: There were 643/657 patients (97.9%) successfully implanted with the OmniaSecure lead with a mean follow-up of 32.4±9.1 months (26% female, 61.9±12.9 years). Pacing capture threshold, pacing impedance, and R-wave amplitudes remained stable throughout. There was a 96.5% freedom from major study lead-related complications at 3 years. At 3 years, 22.3% of patients received appropriate therapies, that is, shock and antitachycardia pacing, with a 75.4% antitachycardia pacing efficacy. Inappropriate shock rate was 2.7% and 5.9% at 1 and 3 years, respectively. CONCLUSIONS: The final results of the LEADR trial demonstrated 3-year term safety, efficacy, and reliability of the OmniaSecure lead, emphasizing the potential utility of this lead in a wide variety of patients.
- 17 December 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (4) , 663-665
The Additional Value of His Ventricular Interval in Left Bundle Branch Block After Transcatheter Aortic Valve Implantation: Precision Medicine or Not?
- 17 December 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (4) , 663-665
The Additional Value of His Ventricular Interval in Left Bundle Branch Block After Transcatheter Aortic Valve Implantation: Precision Medicine or Not?
- Open Access
- 20 November 2025
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 12 (2) , 253-257
Early perforation after attempted conduction system pacing: Lessons from the electrocardiogram
- 20 November 2025
- Published by Elsevier in HeartRhythm Case Reports
- Vol. 12 (2) , 253-257
Open AccessEarly perforation after attempted conduction system pacing: Lessons from the electrocardiogram
- 17 September 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 11 (11) , 2484-2492
Prophylactic Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement
- 17 September 2025
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 11 (11) , 2484-2492
Prophylactic Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement